UK Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

UK Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  110 | No. Tables:  77 | No. Figures:  42

Market Definition

The UK Professional Acne Medication Market was valued at USD 111.3 million in 2023 and is predicted to reach USD 192.925 million by 2030, with a CAGR of 8.2% from 2024 to 2030. The professional acne medication market includes specialized skincare formulations created and prescribed by dermatologists and skincare specialists to treat acne-related issues. Its main goals are to provide focused and efficient remedies for various forms of acne, such as inflammatory and non-inflammatory lesions, as well as to avoid acne scarring. The benefits of professional acne medicine stem from their powerful and personalized formulations, which frequently include clinically validated components that are more potent than over-the-counter equivalents.

These drugs, which are widely used in dermatological offices, cater to those with severe or persistent acne difficulties, providing a better level of effectiveness and control. As the demand for sophisticated skincare treatments grows, the professional acne medication market remains critical in achieving cleaner, healthier skin through individualized and medically directed techniques.

Rising Emphasis on Skin Health Drives the Market Growth

A significant driving force behind the growth of the professional acne medication market is the increasing awareness and concern for skin health. With a growing emphasis on skin health and appearance, individuals in the region are actively seeking ways to achieve and maintain clear, healthy skin. As more people prioritize their skin health and aspire to attain a flawless complexion, the need for effective and expert-driven solutions has surged, making professional acne treatments a vital component of the broader skincare and dermatological landscape in the UK.

 

Rising Demand for Cosmetic Dermatology Drives the Market Growth

The UK has witnessed a substantial increase in the demand for cosmetic dermatology treatments, which encompasses professional acne medication, reflecting a notable trend in the country's healthcare and beauty industry. The surge in demand for professional acne medication is attributed to the population's growing awareness and concern for skin health and appearance. This surge in demand reflects the evolving beauty and wellness landscape in the UK, where individuals prioritize skin health and seek out advanced solutions to address common skin issues like acne, thereby propelling the growth of the professional acne medication market.

 

High Healthcare Costs and Limited Insurance Coverage Hindering Market Growth

The growth of the professional acne medication market in the UK is hampered by high healthcare costs and limited insurance coverage. These financial barriers limit access to specialized dermatological treatments, hindering market expansion. The impact is evident as individuals face challenges affording or securing coverage for professional acne medications, restricting the market's potential for growth in the UK.

Innovative Treatments Represent a Significant Opportunity for the Market

Innovative treatments present a substantial growth opportunity in the UK professional acne medication market. As the market evolves, the integration of advanced dermatological technologies, such as laser therapies and AI-assisted treatment modalities, stands out as a promising avenue. These cutting-edge innovations hold the potential to enhance the effectiveness of professional acne medication, providing patients with personalized and state-of-the-art solutions. With the increasing demand for more efficient, less invasive, and personalized treatments, these innovative approaches align perfectly with the evolving preferences of patients, making them a pivotal driver in expanding the professional acne medication market in the UK.

 

Competitive Landscape

The UK professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

UK Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 111.27 Million

Revenue Forecast in 2030

USD 192.925 Million

Growth Rate

CAGR of 8.2% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Increasing emphasis on skin health skin health.

Increasing demand for cosmetic dermatology treatments.

Key Market Players

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      U.K. PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6       U.K. PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE MARKET

           6.3      NON-INFLAMMATORY ACNE MARKET

7       U.K. PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS MARKET

           7.3      ORAL MEDICATIONS MARKET

8       U.K. PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS MARKET

           8.3      ANTIBIOTICS MARKET

           8.4      SALICYLIC ACID MARKET

           8.5      BENZOYL PEROXIDE MARKET

           8.6      OTHERS MARKET

9       U.K. PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA MARKET

           9.3      AESTHETICIAN MARKET

           9.4      DERMATOLOGIST MARKET

           9.5      OTHER PROFESSIONAL CHANNELS MARKET

10   COMPANY PROFILES

           10.1   ALMIRALL S.A.

                         10.1.1   COMPANY OVERVIEW

                         10.1.2   COMPANY SNAPSHOT

                         10.1.3   OPERATING BUSINESS SEGMENTS

                         10.1.4   PRODUCT PORTFOLIO

                         10.1.5   BUSINESS PERFORMANCE

                         10.1.6   BUSINESS SEGMENTS

                         10.1.7   GEOGRAPHIC SEGMENTS

                         10.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.1.9   PRIMARY MARKET COMPETITORS

           10.2   BAUSCH HEALTH COMPANIES, INC.

                         10.2.1   COMPANY OVERVIEW

                         10.2.2   COMPANY SNAPSHOT

                         10.2.3   OPERATING BUSINESS SEGMENTS

                         10.2.4   PRODUCT PORTFOLIO

                         10.2.5   BUSINESS PERFORMANCE

                         10.2.6   BUSINESS SEGMENTS

                         10.2.7   GEOGRAPHIC SEGMENTS

                         10.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.2.9   PRIMARY MARKET COMPETITORS

           10.3   GLAXOSMITHKLINE PLC (GSK)

                         10.3.1   COMPANY OVERVIEW

                         10.3.2   COMPANY SNAPSHOT

                         10.3.3   OPERATING BUSINESS SEGMENTS

                         10.3.4   PRODUCT PORTFOLIO

                         10.3.5   BUSINESS PERFORMANCE

                         10.3.6   BUSINESS SEGMENTS

                         10.3.7   GEOGRAPHIC SEGMENTS

                         10.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.3.9   PRIMARY MARKET COMPETITORS

           10.4   GALDERMA S.A.

                         10.4.1   COMPANY OVERVIEW

                         10.4.2   COMPANY SNAPSHOT

                         10.4.3   OPERATING BUSINESS SEGMENTS

                         10.4.4   PRODUCT PORTFOLIO

                         10.4.5   BUSINESS PERFORMANCE

                         10.4.6   BUSINESS SEGMENTS

                         10.4.7   GEOGRAPHIC SEGMENTS

                         10.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.4.9   PRIMARY MARKET COMPETITORS

           10.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         10.5.1   COMPANY OVERVIEW

                         10.5.2   COMPANY SNAPSHOT

                         10.5.3   OPERATING BUSINESS SEGMENTS

                         10.5.4   PRODUCT PORTFOLIO

                         10.5.5   BUSINESS PERFORMANCE

                         10.5.6   BUSINESS SEGMENTS

                         10.5.7   GEOGRAPHIC SEGMENTS

                         10.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.5.9   PRIMARY MARKET COMPETITORS

           10.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         10.6.1   COMPANY OVERVIEW

                         10.6.2   COMPANY SNAPSHOT

                         10.6.3   OPERATING BUSINESS SEGMENTS

                         10.6.4   PRODUCT PORTFOLIO

                         10.6.5   BUSINESS PERFORMANCE

                         10.6.6   BUSINESS SEGMENTS

                         10.6.7   GEOGRAPHIC SEGMENTS

                         10.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.6.9   PRIMARY MARKET COMPETITORS

           10.7   JOHNSON AND JOHNSON

                         10.7.1   COMPANY OVERVIEW

                         10.7.2   COMPANY SNAPSHOT

                         10.7.3   OPERATING BUSINESS SEGMENTS

                         10.7.4   PRODUCT PORTFOLIO

                         10.7.5   BUSINESS PERFORMANCE

                         10.7.6   BUSINESS SEGMENTS

                         10.7.7   GEOGRAPHIC SEGMENTS

                         10.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.7.9   PRIMARY MARKET COMPETITORS

           10.8   ELI LILLY AND COMPANY

                         10.8.1   COMPANY OVERVIEW

                         10.8.2   COMPANY SNAPSHOT

                         10.8.3   OPERATING BUSINESS SEGMENTS

                         10.8.4   PRODUCT PORTFOLIO

                         10.8.5   BUSINESS PERFORMANCE

                         10.8.6   BUSINESS SEGMENTS

                         10.8.7   GEOGRAPHIC SEGMENTS

                         10.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.8.9   PRIMARY MARKET COMPETITORS

           10.9   MYLAN N.V.

                         10.9.1   COMPANY OVERVIEW

                         10.9.2   COMPANY SNAPSHOT

                         10.9.3   OPERATING BUSINESS SEGMENTS

                         10.9.4   PRODUCT PORTFOLIO

                         10.9.5   BUSINESS PERFORMANCE

                         10.9.6   BUSINESS SEGMENTS

                         10.9.7   GEOGRAPHIC SEGMENTS

                         10.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.9.9   PRIMARY MARKET COMPETITORS

           10.10   DAIICHI SANKYO COMPANY, LTD

                         10.10.1   COMPANY OVERVIEW

                         10.10.2   COMPANY SNAPSHOT

                         10.10.3   OPERATING BUSINESS SEGMENTS

                         10.10.4   PRODUCT PORTFOLIO

                         10.10.5   BUSINESS PERFORMANCE

                         10.10.6   BUSINESS SEGMENTS

                         10.10.7   GEOGRAPHIC SEGMENTS

                         10.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 4. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 7. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 13. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 18. ALMIRALL S.A.: COMPANY SNAPSHOT

TABLE 19. ALMIRALL S.A.: OPERATING BUSINESS SEGMENTS

TABLE 20. ALMIRALL S.A.: PRODUCT PORTFOLIO

TABLE 21. ALMIRALL S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 22. ALMIRALL S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 23. ALMIRALL S.A.: KEY STRATERGY

TABLE 24. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 25. BAUSCH HEALTH COMPANIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 26. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 27. BAUSCH HEALTH COMPANIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 28. BAUSCH HEALTH COMPANIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 29. BAUSCH HEALTH COMPANIES, INC.: KEY STRATERGY

TABLE 30. GLAXOSMITHKLINE PLC (GSK): COMPANY SNAPSHOT

TABLE 31. GLAXOSMITHKLINE PLC (GSK): OPERATING BUSINESS SEGMENTS

TABLE 32. GLAXOSMITHKLINE PLC (GSK): PRODUCT PORTFOLIO

TABLE 33. GLAXOSMITHKLINE PLC (GSK): SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 34. GLAXOSMITHKLINE PLC (GSK): SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 35. GLAXOSMITHKLINE PLC (GSK): KEY STRATERGY

TABLE 36. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 37. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 38. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 39. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 40. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 41. GALDERMA S.A.: KEY STRATERGY

TABLE 42. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 43. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 44. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 45. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 46. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 47. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGY

TABLE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS

TABLE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 53. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

TABLE 54. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 55. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 56. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 57. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 58. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 59. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 60. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 61. ELI LILLY AND COMPANY: OPERATING BUSINESS SEGMENTS

TABLE 62. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 63. ELI LILLY AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 64. ELI LILLY AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 65. ELI LILLY AND COMPANY: KEY STRATERGY

TABLE 66. MYLAN N.V.: COMPANY SNAPSHOT

TABLE 67. MYLAN N.V.: OPERATING BUSINESS SEGMENTS

TABLE 68. MYLAN N.V.: PRODUCT PORTFOLIO

TABLE 69. MYLAN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 70. MYLAN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 71. MYLAN N.V.: KEY STRATERGY

TABLE 72. DAIICHI SANKYO COMPANY, LTD: COMPANY SNAPSHOT

TABLE 73. DAIICHI SANKYO COMPANY, LTD: OPERATING BUSINESS SEGMENTS

TABLE 74. DAIICHI SANKYO COMPANY, LTD: PRODUCT PORTFOLIO

TABLE 75. DAIICHI SANKYO COMPANY, LTD: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 76. DAIICHI SANKYO COMPANY, LTD: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 77. DAIICHI SANKYO COMPANY, LTD: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 9. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 12. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 18. UK PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 23. ALMIRALL S.A.: NET SALES, (2021-2023)

FIGURE 24. ALMIRALL S.A.: PRIMARY MARKET COMPETITORS

FIGURE 25. BAUSCH HEALTH COMPANIES, INC.: NET SALES, (2021-2023)

FIGURE 26. BAUSCH HEALTH COMPANIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 27. GLAXOSMITHKLINE PLC (GSK): NET SALES, (2021-2023)

FIGURE 28. GLAXOSMITHKLINE PLC (GSK): PRIMARY MARKET COMPETITORS

FIGURE 29. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 30. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 31. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, (2021-2023)

FIGURE 32. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 33. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2021-2023)

FIGURE 34. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS

FIGURE 35. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 36. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 37. ELI LILLY AND COMPANY: NET SALES, (2021-2023)

FIGURE 38. ELI LILLY AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 39. MYLAN N.V.: NET SALES, (2021-2023)

FIGURE 40. MYLAN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 41. DAIICHI SANKYO COMPANY, LTD: NET SALES, (2021-2023)

FIGURE 42. DAIICHI SANKYO COMPANY, LTD: PRIMARY MARKET COMPETITOR

KEY PLAYERS

  • Almirall SA

  • Bausch Health Companies, Inc.

  • GlaxoSmithKline Plc (GSK)

  • Galderma SA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Johnson & Johnson

  • STRATA Skin Sciences, Inc.

  • Mayne Pharma Group Limited

  • Pfizer, Inc.


Frequently Asked Questions
What will be the worth of the UK professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the UK professional acne medication market business is expected to hit at USD 192.925 million by 2030.

What are the leading companies in the UK professional acne medication market?

The UK professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

What are the market segmentations and scope of the study for the UK professional acne medication industry?

The UK professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in the UK?

The growth of the professional acne medication market in the UK is primarily driven by increasing awareness and concern for skin health and an increase in the demand for cosmetic dermatology treatments.

What is restraining the growth of the UK professional acne medication market?

The high healthcare costs and limited insurance coverage present a substantial restraint on the market's growth in the UK